Caroline Korves

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1724214/publications.pdf

Version: 2024-02-01

1684188 1588992 91 14 5 8 citations h-index g-index papers 15 15 15 188 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Real-world Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Newly Treated Korean Patients With Asthma: A Retrospective Cohort Study. Allergy, Asthma and Immunology Research, 2022, 14, 220.	2.9	3
2	Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. Prostate Cancer and Prostatic Diseases, 2021, 24, 210-219.	3.9	11
3	Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease. Clinical Ophthalmology, 2021, Volume 15, 1041-1054.	1.8	13
4	Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A U.S. tertiary oncology center analysis Journal of Clinical Oncology, 2020, 38, 223-223.	1.6	0
5	Public health impact of Rotarix vaccination among commercially insured children in the United States. Vaccine, 2017, 35, 5065-5072.	3.8	2
6	Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States. PLoS ONE, 2016, 11, e0145977.	2.5	13
7	A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer, 2015, 15, 175.	2.6	24
8	Resource utilization and costs following hospitalization of patients with chronic heart failure in the US. Journal of Medical Economics, 2012, 15, 925-937.	2.1	22
9	Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy Journal of Clinical Oncology, 2012, 30, 10061-10061.	1.6	O
10	Abstract P2: Medical Resource Utilization and Costs Following Hospitalization of Patients with Chronic Heart Failure in the United States. Circulation: Cardiovascular Quality and Outcomes, 2011, 4,	2.2	0
11	Abstract P116: Hospitalization Due to Heart Failure is Associated With Significant Medical Resource Utilization and Costs. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	2.2	O
12	The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States. Blood, 2010, 116, 2563-2563.	1.4	1
13	Monitoring and Treatment of Transfusional Iron Overload: Findings from an Electronic Medical Records Review Study at the Moffitt Cancer Center and Research Institute Blood, 2010, 116, 1503-1503.	1.4	O
14	The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States Blood, 2009, 114, 1379-1379.	1.4	0